You are here

Update on NICE MTAs

Update on the NICE MTAs of 2nd generation TKIs for CML.

The results of the Appeal against the NICE FAD  for the MTA: dasatinib, nilotinib and high dose imatinib in imatinib intolerant and resistant CML , and the resultant TAG (TA241 Full Guidance) will be published on the NICE website on Friday 13th January 2012.

CMLSg  presented NICE with our official comments on the current ACD for MTA: dasatinib and nilotinib for 1st line use in chronic phase CML.

The resultant AC meeting for this MTA, that will consider all official comments will be on February 11th at NICE offices in Manchester. Members of the public can apply to attend this meeting as observers. This can be done through the NICE website.

Best wishes,

Sandy